Ascendis Pharma (ASND) Misses Q1 EPS by 14c, Miss on Revenues

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of ($0.87), $0.14 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $416 thousand versus the consensus estimate of $1.37 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Ennis (EBF) Reports In-Line Q1 EPS